StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
SLNBullishIndustry Newsnews
High materiality8/10

Silence's Divesiran Demonstrates Durable PV Benefits; Phase 2 Topline Due Aug 2026

Jun 11, 2026, 7:34 AM EDT2 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Positive Phase 1 signals and a near-term Phase 2 catalyst could lift SLN shares, particularly if topline confirms durable phlebotomy reductions and safety. Yet, the lack of a surefire path to approval means upside is contingent on Phase 2 results and execution.

AI summary

What happened, with direct paths to the underlying reporting

Silence Therapeutics reported favorable Phase 1 SANRECO data for divesiran in polycythemia vera, with sustained phlebotomy reductions and improved symptoms and quality of life. Follow-up data show phlebotomy usage stayed low after the final dose, while the Phase 2 SANRECO trial with Q6W and Q12W regimens remains on track for topline results in August 2026, potentially validating a flexible, dosing-favorable therapy.

  • Phase 1 SANRECO in PV shows symptom/QoL improvements. Phlebotomy reductions persist after final dose.
  • 21 PV patients. 80 pre-treatment phlebotomies vs 5 during active treatment.
  • 16-week follow-up after final dose saw only 4 phlebotomies.
  • Median time to first phlebotomy: 287 days (n=14).
  • Phase 2 SANRECO topline due August 2026; Q6W and Q12W dosing on-track.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event